Research programme: antibacterials - AmoebicsAlternative Names: antibody-protein therapeutics -Amoebics; VenFc
Latest Information Update: 16 Apr 2007
At a glance
- Originator Amoebics
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Staphylococcal infections
Most Recent Events
- 16 Apr 2007 This programme is still in active development
- 25 Jan 2006 Preclinical trials in Staphylococcal infections in United Kingdom (unspecified route)